Number crunching and thoughts below
$145.43 for outpatient reimbursement per test from medicare to hospital (remember IPD does not get paid per test only by licence for each SOZO sold or leased)
Before inclusion into NCCN guidelines
50000 patients last quarter per Q223 report.
estimated 7M per quarter. So the licence fees should come close to hospital reimbursement. Licence fees now need to go up more but this does get a bit complicated as some hospitals will have more patients than others making the SOZO unit more cost effective at some hospitals and not at others.
Break even
Reverse engineered for USA market to get to break even (30,000,000 AUD)
Estimated in USD below for licence fee per month.
$20,000,000.00 USD / 900 SOZO /12 = $1851 per SOZO unit for break even or $20,000,000 / 700 SOZO /12 =$2380 (the licences must be very cheap atm).
USA estimate 900 SOZO x $5000 *12 = $54,000,000. est earnings of 0.03 a share
USA estimate 3000 SOZO x $5000*12=$180,000,000. est earnings of 0.10 a share
USA estimate 10000 SOZO x $5000*12=$600,000,000.est earnings of 0.30 a share
$60000000/145 = 4,137931 patients tests a year, is this realistic number of patients that will be tested or pie in the sky?
SOZO has the add in modules for to justify higher prices. The clinicians really like the add ons, they show the data to the patients, the patients can see what's going on and the patient can change their behaviour to get the desired outcome.
Bone
Malnutrition
Hydration
might be 1 more but I forget.
Where is my logic wrong?
It costs the market 1B a year to treat lymphedema so SOZO should cost less than that to be a benefit for that market.
It's not just gouge the market, everything has to be based around what medicare and what the private payers pay in reimbursement.
The key is the number of patients tested x reimbursement.
Regards
Acclivity
Expand
